Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline

Journal of Clinical Pharmacology

Volumn 55, Issue 5, 2015, Pages 534-542

  Davenport, J Michael ^a   Covington, Paul ^a   Bonifacio, Laura ^a   McIntyre, Gail ^a   Venitz, Jürgen ^a,b  

^a Furiex Pharmaceuticals Inc   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

cyclosporine; drug interaction; eluxadoline; pharmacokinetics; probenecid

Indexed keywords

CYCLOSPORIN; ELUXADOLINE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTER 3; PROBENECID; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; IMIDAZOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTER; PHENYLALANINE; SLCO1B1 PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXPOSURE; DRUG SAFETY; DRUG UPTAKE; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; KIDNEY CLEARANCE; KIDNEY PROXIMAL TUBULE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PROSPECTIVE STUDY; RANDOMIZATION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; CONTROLLED STUDY; HALF LIFE TIME; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOSPORINE; HALF-LIFE; HUMANS; IMIDAZOLES; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHENYLALANINE; PROBENECID; SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 1B1;

EID: 84961311660     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.442     Document Type: Article

References (25)

1. Wade P, Palmer J, McKenney S, et al. Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/μ opioid receptor antagonist. Br J Pharmacol. 2012; 167: 1111-1125.
2. Covington PS, Andrae D, Dove S, et al. MuDelta treatment improves bowel movement frequency and urgency episodes in patients with diarrhea-predominant irritable bowel syndrome: results of a phase 2 clinical trial. Gastroenterology. 2012; 142 (1): S161.
3. Dove LS, Lembo A, Randal CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013; 145: 329-338.
4. Fujita W, Gomes I, Dove S, Prohaska D, McIntyre G, Devi L,. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol. 2014; 92 (3): 448-456.
5. Breslin H, Diamond C, Kavash R, Cai C, Dyatkin A, Miskowski T,. Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant irritable bowel syndrome (IBS-d). Bioorganic Med Chem Lett. 2012; 22 (14): 4869-4872.
6. Giacomini K, Huang S, Tweedie D, et al. Membrane transporters in drug development. Drug Discovery. 2010; 9: 215-236.
7. Niemi M, Pasanen M, Neuvonen P,. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011; 63: A-Y.
8. Karlgren M, Ahlin G, Bergström C, Svensson R, Palm J, Artursson P,. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res. 2012; 29 (2): 411-426.
9. Kalliokoski A, Niemi M,. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009; 158: 693-705.
10. Food and Drug Administration Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Draft Guidance. 2012.
11. Mahmood I, Martinez M, Hunter R,. Interspecies allometric scaling. Part I: prediction of clearance in large animals. J. Vet. Pharmacol Therap. 2006; 29: 415-423.
12. Herédi-Szabõ K, Jemnitzb K, Kisa E, et al. Potentiation of MRP2/Mrp2-mediated estradiol-17b-glucuronide transport by drugs-a concise review. Chem Biodiversity. 2009; 6: 1970-1974.
13. Mor-Cohen R, Zivelin A, Rosenberg N, Shani M, Muallem S, Seligsohn U,. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem. 2001; 276 (40): 36923-36930.
14. Kamisako T, Leier I, Cui Y, et al. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999; 30 (2): 485-490.
15. van Gelder T, Klupp J, Barten MJ, Christians U, Morris R,. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001; 23 (2): 119-128.
16. Kuypers DR, Ekberg H, Grinyõ J, et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet. 2009; 48 (5): 329-341.
17. Barbara J, Brennan B, Moreira S, et al. Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin. Clin Pharmacokinet. 2013; 52: 805-813.
18. Kovarik Noe JA, Wang Y, Mueller I, DeNucci G, Schmouder R,. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus. Eur J Clin Pharmacol. 2006; 62: 361-366.
19. Kovarika J, Stitaha S, Sladea A, et al. Sotrastaurin and cyclosporine drug interaction study in healthy subjects. Biopharm. Drug Dispos. 2010; 31: 331-339.
20. Mueller E, Kovarik J, Koelle E, Merdjan H, Johnston A, Hitzenberger G,. Pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration. J Clin Pharmacol. 1993; 33: 936-943.
21. Potschka H, Fedrowitz M, Loüscher W,. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. JPET. 2003; 306: 124-131.
22. Janneha O, Owena A, Chandlera B, et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS. 2005; 19: 2097-2102.
23. Horikawa M, Kato Y, Tyson C, Sugiyama Y,. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metabol. Pharmacokin. 2002; 17 (1): 23-33.
24. Bakos E, Evers R, Sinkõ E, Váradi A, Borst P, Sarkadi B,. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000; 57: 760-768.
25. Chen C, Scott D, Hanson E, et al. Impact of MRP2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Pharmaceutical Res. 2003; 20 (1): 31-37.